Decreased vertigo severity, comorbidity burden, and absence of hearing loss tied to conservative treatment response<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 6, 2023 (HealthDay News) — A three-factor, composite clinical severity staging system can optimize treatment selection for the management of Meniere disease, according to a study published online Aug. 25 in Otolaryngology — Head and Neck Surgery<\/em>.<\/p>\n Brevin J. Miller, from Washington University in St. Louis, and colleagues sought to identify clinically important factors associated with conservative treatment response in Meniere disease and to develop a composite clinical severity staging system. Seventy-eight patients were enrolled in the study.<\/p>\n The researchers found that 63 percent of patients were responsive to conservative therapies. Higher proportions of no or mild vertigo (24 percent) and none or mild comorbidity (27 percent) and a lower proportion of hearing loss (19 percent) were seen among responsive versus unresponsive patients. A three-stage system that consolidated these factors demonstrated a treatment response gradient ranging from 100 percent for stage 1 (11 patients), 64 percent for stage 2 (56 patients), and 18 percent for stage 3 (11 patients).<\/p>\n “A composite clinical severity staging system including these three factors can be used to optimize treatment selection and promote patient-centered management of Meniere’s disease,” the authors write.<\/p>\n One author reported being a consultant for Cochlear Ltd. <\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n